Delivering clarity for a better tomorrow.

Delivering clarity for a
better tomorrow.

PROSTATENOW™ is a comprehensive germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.

Covered by Medicare for

qualifying patients

Powered by NorthShore 

University HealthSystem

Recommended by new 

NCCN guidelines

The genetics of prostate cancer.

Inherited factors account for 57% of the risk for developing prostate cancer. The heritability of prostate cancer is stronger compared to other cancers such as breast cancer, ovarian cancer and colorectal cancer. This highlights the importance of assessing the inherited risk for prostate cancer.

Inherited risk can be assessed using
three available methods:

Hereditary Family History

Family History (FH)

FH is a common but indirect measurement of inherited risk.
Men with a positive FH have a 1.5-to-2.5-fold increased risk for developing prostate cancer.

Rare Pathogenic Mutations

Rare Pathogenic Mutations (RPMS)

RPMs are pathogenic DNA mutations in the coding regions of genes such as BRCA2, ATM, and CHEK2.
Rare and are associated with a moderate-to-high risk for developing prostate cancer. Also associated with prostate cancer aggressiveness.

Genetic Risk Score (GRS)

Calculated based on more than 100 single nucleotide polymorphisms (SNPs) associated with prostate cancer risk.
Used to assess a man’s risk of developing prostate cancer compared to other men in the general population.

Currently, genetic tests only account for one or two of these methods, leaving patients with an incomplete assessment of one's inherited risk for prostate cancer.

PROSTATENOW

delivers answers with
unmatched clarity.

PROSTATENOW

delivers answers with unmatched clarity.

PROSTATENOW™ is the only test today that assesses a patient’s risk based on all three methods – FH, RPMs, and GRS. 

 

PROSTATENOW™ is a new, clinical grade, comprehensive germline panel and is powered by the urology team of NorthShore University HealthSystem.  

Benefits of PROSTATENOW

Predicting prognosis for localized prostate cancer patients

Information on RPMs can supplement traditional clinical variables such as Gleason Score and PSA levels to predict disease progression and inform personalized decisions on prostate cancer treatment such as pursuing active surveillance vs. definitive treatment with either surgery or radiation.

Predicting therapeutic responses for advanced prostate cancer patients

RPMs in DNA repair genes and other genes can complement clinical variables and somatic DNA testing when making a personalized decision on drug treatments.

Predicting risk for unaffected men:

Men with RPMs and a higher GRS may evaluate their chances of passing on this risk to their offspring and consider early and more frequent prostate cancer screening.

Leveraging big data to improve results.

Includes both RPMs and GRS from studies involving multiple races.

PROSTATENOW™ includes all known prostate cancer susceptibility genes as well as >100 prostate cancer risk-associated SNPs for calculating GRS in multiple races. 

Comprehensive evaluation of
current evidence.

PROSTATENOW™ is developed based on recommendations from up-to-date clinical guidelines, current evidence review, and proprietary data from the NorthShore team. 

The largest mutation database:

In addition to following the mutation-calling guidelines of American College of Medical Genetics (ACMG), we have the largest germline mutation database with data gathered from more than 300,000 men with or without prostate cancer. This information helps categorize relevant mutations in prostate cancer to provide accurate results.

Test Panel

ATM

GEN1

MLH1

ATR

MRE11A

MSH2

BRCA1

NBN

MSH6

BRCA2

PALB2

PMS2

BRIP1

RAD51C

HOXB13

CHEK2

RAD51D

HSD3B1

FAM175A

TP53

SNP-Based GRS

FANCA

EPCAM

We're here to guide you
through the process.

Part of PROSTATENOW™ includes genetic counseling to walk you through our process and test results, along with any lifestyle or treatment alternatives depending on your results. 

The technology powering PROSTATENOW™ – clinically valid and utilized.

The clinical validity and utility of RPMs and GRS in cancer risk assessment – key technology components of PROSTATENOW™ – are supported by hundreds of peer-reviewed papers published by the NorthShore team, including the following key publications in leading journals.

Published: Nov. 28, 2020

Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality

Article Conclusion:

This population-based prospective study suggests that GRS complements two guideline-recommended inherited risk measures (FH and RPMs) for stratifying the risk of PCa incidence and mortality.

Authors:

Zhuqing Shi, Elizabeth A Platz, Jun Wei, Rong Na, Richard J Fantus, Chi-Hsiung Wang, Scott E Eggener, Peter J Hulick, David Duggan, S Lilly Zheng, Kathleen A Cooney, William B Isaacs, Brian T Helfand, Jianfeng Xu

Single-Nucleotide Polymorphism–Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis

Published: Dec. 27, 2019

Article Conclusion:
This study suggests that a GRS is significantly associated with patient age at PCa diagnosis. Combining FH and GRS may better stratify inherited risk than FH alone for developing personalized PCa screening strategies.

Germline Mutations in HOXB13 and Prostate-Cancer Risk

Published: Jan. 12, 2012

Article Conclusion:
The novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer. Although the variant accounts for a small fraction of all prostate cancers, this finding has implications for prostate-cancer risk assessment and may provide new mechanistic insights into this common cancer. (Funded by the National Institutes of Health and others.)

Cumulative Association of Five Genetic Variants with Prostate Cancer

Published: Feb. 28, 2008

Article Conclusion:
This study suggests that a GRS is significantly associated with patient age at PCa diagnosis. Combining FH and GRS may better stratify inherited risk than FH alone for developing personalized PCa screening strategies.

Bringing PROSTATENOW™ to you.

Simplified.

Discussion with your Physician​

Speak with your physician about receiving a referral for PROSTATENOW™.

Sample Collection​

The test can be performed using blood or saliva sample collections. If using saliva, we will send the collection kit to your home where you will supply the sample yourself. However, if choosing the blood kit, the sample will be collected at a medical facility.​

Your Sample is Analyzed
in our Lab​

GoPath will run PROSTATENOW™, analyzing your genes, collecting data about any RPMs, and analyzing your GRS.​

Results + Genetic Counseling​

Your report will be available within 10-14 days. A GoPath genetic counselor will be assigned to you to discuss test results and next steps. ​

PROSTATENOW™ is covered by Medicare for qualifying patients.

NCCN guidelines recommend germline testing for men with prostate cancer, and patients with a high-risk family history, intraductal histologies, or other conditions, regardless of risk. These recommendations are also for unaffected men with a family history of hereditary cancer syndromes and a family history of pathogenic mutations.

Additional Resources